Krishnamohan Neha — SEC insider filings
SEC reporting owner CIK 1866171. 22 insider filings on record with FilingPulse; latest filed 2026-11-18.
Transaction summary — filings shown
Covers all 22 filings on record, filed 2021-06-08 to 2026-11-18. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 2 legs across 1 filing — 40,504 shares, $939,494 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 33.
- Largest priced transaction: sale of 39,272 shares @ $23.19 ($910,702) in Arcutis Biotherapeutics, Inc., filed 2025-11-17.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | Director | 6 | — | 2 legs · 40,504 sh · $939,494 | 13 |
| Kinnate Biopharma Inc. (KNTE) | CHIEF FINANCIAL OFFICER | 11 | — | — | 14 |
| Artiva Biotherapeutics, Inc. (ARTV) | Chief Financial Officer | 4 | — | — | 5 |
| Latigo Biotherapeutics, Inc. (LTGO) | CFO and Chief Business Officer | 1 | — | — | 1 |
Insider filings — Krishnamohan Neha
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-18 | 4 | Latigo Biotherapeutics, Inc. (LTGO) | Grant/award (A): 175,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Grant/award (A): 5,778 @ $0 · Grant/award (A): 16,667 (derivative) @ $0 | EDGAR |
| 2025-11-17 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Option exercise (M): 27,052 @ $8.63 · Option exercise (M): 12,220 @ $7.51 · Sale (S): 39,272 @ $23.19 · Sale (S): 1,232 @ $23.37 · Option exercise (M): 27,052 (derivative) @ $0 · Option exercise (M): 12,220 (derivative) @ $0 | EDGAR |
| 2025-11-17 | 4 | Artiva Biotherapeutics, Inc. (ARTV) | Tax withholding (F): 3,490 @ $3.25 | EDGAR |
| 2025-08-18 | 4 | Artiva Biotherapeutics, Inc. (ARTV) | Tax withholding (F): 1,341 @ $2.13 · Tax withholding (F): 5,813 @ $2.75 | EDGAR |
| 2025-06-16 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Grant/award (A): 7,609 @ $0 · Grant/award (A): 20,568 (derivative) @ $0 | EDGAR |
| 2025-02-28 | 4 | Artiva Biotherapeutics, Inc. (ARTV) | Grant/award (A): 60,000 @ $0 | EDGAR |
| 2024-09-13 | 4 | Artiva Biotherapeutics, Inc. (ARTV) | Grant/award (A): 50,000 @ $0 | EDGAR |
| 2024-06-18 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Grant/award (A): 10,139 @ $0 · Grant/award (A): 27,052 (derivative) @ $0 | EDGAR |
| 2024-04-05 | 4 | Kinnate Biopharma Inc. (KNTE) | Disposition to issuer (D): 64,087 · Disposition to issuer (D): 270,000 (derivative) · Disposition to issuer (D): 185,000 (derivative) · Disposition to issuer (D): 215,000 (derivative) | EDGAR |
| 2024-03-05 | 4 | Kinnate Biopharma Inc. (KNTE) | Tax withholding (F): 1,506 @ $2.59 | EDGAR |
| 2023-12-05 | 4 | Kinnate Biopharma Inc. (KNTE) | Tax withholding (F): 1,459 @ $2.25 | EDGAR |
| 2023-09-06 | 4 | Kinnate Biopharma Inc. (KNTE) | Tax withholding (F): 1,459 @ $2.35 | EDGAR |
| 2023-06-05 | 4 | Kinnate Biopharma Inc. (KNTE) | Tax withholding (F): 1,459 @ $4.30 | EDGAR |
| 2023-06-02 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Grant/award (A): 4,375 @ $0 · Grant/award (A): 12,220 (derivative) @ $0 | EDGAR |
| 2023-03-03 | 4 | Kinnate Biopharma Inc. (KNTE) | Tax withholding (F): 1,721 @ $5.21 | EDGAR |
| 2023-02-14 | 4 | Kinnate Biopharma Inc. (KNTE) | Grant/award (A): 215,000 (derivative) @ $0 | EDGAR |
| 2022-12-02 | 4 | Kinnate Biopharma Inc. (KNTE) | Tax withholding (F): 1,459 @ $7.75 | EDGAR |
| 2022-09-06 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Grant/award (A): 29,482 (derivative) @ $0 | EDGAR |
| 2022-09-02 | 4 | Kinnate Biopharma Inc. (KNTE) | Grant/award (A): 67,500 @ $0 | EDGAR |
| 2022-02-15 | 4 | Kinnate Biopharma Inc. (KNTE) | Grant/award (A): 185,000 (derivative) @ $0 | EDGAR |
| 2021-06-08 | 4 | Kinnate Biopharma Inc. (KNTE) | Grant/award (A): 270,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-10-02 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1866171 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs